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==========

The mechanism of the short-term effects of sitagliptin is unclear.In the very short-term (after 3 days) sitagliptin treatment, the postprandial glucose concentration in Japanese patients with newly diagnosed or uncontrolled type 2 diabetes mellitus was significantly lower than the concentration on the day before sitagliptin treatment started (i.e., on the first day of the calorie-restricted diet).This result may be partly attributable to sitagliptin rapidly suppressing excessive glucagon secretion.

Introduction {#Sec1}
============

According to the 2007 National Health and Nutrition Survey, undertaken by the Japanese Ministry of Health, Labour and Welfare, the total number of Japanese persons with prediabetes or diabetes mellitus, and for whom diabetes is strongly suspected or cannot be ruled out, is estimated to be 22.1 million \[[@CR1]\]. Compared with 10 years ago, the number of people suspected to have diabetes has increased by about 1.3 times, and it continues to rise. Indeed, the number of persons with type 2 diabetes is increasing in every country \[[@CR2]\]. In 2011, 366 million people worldwide were reported to have diabetes, and this figure is predicted to increase to 552 million by 2030 \[[@CR2]\].

Unfortunately, efforts to reduce the number of patients with type 2 diabetes have been unsuccessful, despite the availability of a range of oral antidiabetic agents and various types of insulin derivatives. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which work through mechanisms that differ from those of antidiabetics and insulins, and can be used either alone or in combination with them, have been introduced to the global market. Sitagliptin is a DPP-4 which has a favorable efficacy and safety profile that has been validated in many countries \[[@CR3]\], and evidence supporting its use is accumulating in Japan \[[@CR4]--[@CR8]\]. However, the mechanism of the short-term effects of sitagliptin that lower glucose concentrations has yet to be completely elucidated.

One of the clinical benefits of sitagliptin is that it is associated with minimal adverse effects compared with other oral hypoglycemic agents. Therefore, it can be used safely by elderly persons, who are at increased risk of hypoglycemia. Moreover, weight gain and other gastrointestinal adverse effects are uncommon in patients receiving sitagliptin \[[@CR9]\].

Incretins are gut-derived hormones that are secreted from K and L cells in response to nutrients, especially carbohydrates and fat. The two major incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), enhance glucose-dependent insulin secretion from β cells. Moreover, GLP-1 may play an important role in the biosynthesis and secretion of insulin itself, and it suppresses excessive glucagon secretion from α cells in the pancreas. Both incretins are rapidly degraded by the protein-digesting enzyme DPP-4. Sitagliptin exerts its antidiabetic actions through the incretin pathway by inhibiting the activity of DPP-4 \[[@CR10]\].

Despite previous studies that evaluated the effects of sitagliptin on glucagon secretion and blood glucose concentration, to our knowledge, the effects of sitagliptin in the very short-term have not been fully investigated. Therefore, we performed an observational study to determine the very short-term effects of sitagliptin on plasma concentrations of insulin, incretins, and glucagon.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

Patients admitted to our department (Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan) were eligible to participate in the study if they had newly diagnosed or uncontrolled type 2 diabetes with a glycosylated hemoglobin (HbA~1c~) value ≥6.1 % (National Glycohemoglobin Standardization Program). The enrollment period was between April 2010 and September 2012. The following patients were excluded from the study: those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes; those scheduled for or who had undergone surgery; those with a severe infection or serious injury; pregnant, possibly pregnant, and lactating women; those with moderate or severe kidney dysfunction (creatinine clearance \<30 mL/min; and serum creatinine ≥1.5 mg/dL in men and ≥1.3 mg/dL in women); and those receiving insulin treatment.

The study was performed in accordance with the Declaration of Helsinki. Patients were fully informed about the study and gave written informed consent voluntarily. The study protocol was approved by the ethics committee of Hyogo College of Medicine. The study was registered retrospectively on the UMIN Clinical Trials Registry (<http://www.umin.ac.jp/ctr/index.htm>) under the unique trial number UMIN000012642.

Treatment {#Sec4}
---------

For patients receiving diet and exercise therapy before admission, sitagliptin 50 mg/day was used alone. Patients using antidiabetic agents other than DPP-4 inhibitors before admission were instructed to continue the treatment. For those receiving oral medication in addition to diet and exercise therapy, sitagliptin 50 mg/day was added as part of combination drug therapy. If symptomatic hypoglycemia was found after the addition of sitagliptin, the concomitant antidiabetic agent was reduced or discontinued.

Meal Tolerance Tests {#Sec5}
--------------------

JANEF E460F18^®^ (Kewpie Corporation, Tokyo, Japan), containing a total of 460 kcal (carbohydrate 56.5 g, protein 18 g, and lipid 18 g), was used for the meal tolerance tests (MTTs). On day 1 of admission, patients started an energy-restricted diet (25 kcal/kg daily). On day 2, the first MTT was performed to measure baseline values; treatment with sitagliptin 50 mg/day also began on day 2. Three days later, on day 5, the second MTT was performed to allow evaluation of changes in relevant laboratory values. In each MTT, blood samples were collected 10 min before and 0, 15, 30, 60, 120, and 240 min after the meal.

The following laboratory values were measured: plasma glucose (PG), HbA~1c~, glycoalbumin (GA), urinary C-peptide immunoreactivity, immunoreactive insulin (IRI), intact proinsulin, glucagon, active GLP-1, and total GIP. Glucose, HbA~1c~, and GA were measured by enzyme methods; IRI by chemiluminescent immunoassay; intact proinsulin by ELISA; and glucagon by double-antibody radioimmunoassay. Sample tubes containing aprotinin and EDTA-2Na were used for measurement of active GLP-1 and total GIP. A blood sample containing DPP-4 inhibitor10 μg per 1 mL of blood was inserted into the sample tube. The samples were centrifuged immediately to separate the plasma, and then stored at −80 °C. Glucagon-Like Peptide-1 (Active) ELISA kit (Millipore, St. Charles, MO, USA) was used to measure active GLP-1. Human GIP (Total) ELISA kit (Millipore) was used to measure total GIP.

The coefficients of variation of active GLP-1 were 8.0 % in intra-assay and 7.4 % in inter-assay evaluations. Those of human GIP (total) were 6.5 % in intra-assay and 3.48 % in inter-assay evaluations. The detection limit of the GLP-1 and GIP kits were 2.0 pmol/L and 4.2 pg/mL, respectively. Two indices, the homeostasis model assessment (HOMA) for insulin resistance (HOMA-IR) and for β cell function (HOMA-β), were calculated using the following formulae:$$\documentclass[12pt]{minimal}
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Statistical Analysis {#Sec6}
--------------------

Measurements were plotted, and area under the concentration--time curves (AUCs) from time zero to 2 h (AUC~0--2h~) and to 4 h (AUC~0--4h~) were calculated by using the trapezoidal rule. Data are expressed as numbers or means ± standard deviation or as medians with quartile values (25 %, 75 %). The two-way repeated measured ANOVA with ad hoc multiple comparison method (Fisher's least significant difference procedure) was used to compare baseline (0 min) and postprandial laboratory values, as well as values before (i.e., on the first day of the calorie-restricted diet) and after sitagliptin treatment. Changes in AUCs before and 3 days after sitagliptin treatment were analyzed by paired *t* test or Wilcoxon signed rank test according to whether or not the data had normal distribution. A *p* value \<0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Table [1](#Tab1){ref-type="table"} summarizes the baseline characteristics of the 15 patients enrolled. Most patients were receiving oral antidiabetic therapy before study entry, but their glycemic metabolism had not been well-controlled \[mean fasting blood glucose and HbA~1c~ were 154 mg/dL (8.5 mmol/L) and 8.6 %, respectively\]. Throughout the study period, none of the patients required changes to any concomitant antidiabetic agents.Table 1Patient characteristics at baseline (*n* = 15)Characteristic*n* or mean ± SDMale/female8/7Age (years)64.7 ± 10.5Body mass index (kg/m^2^)23.7 ± 3.8Duration of diabetes mellitus (years)10.1 ± 7.1Glycosylated hemoglobin value (%)8.56 ± 1.80Fasting plasma glucose \[mg/dL (mmol/L)\]154 ± 39 (8.5 ± 2.2)Immunoreactive insulin (μU/mL)4.95 ± 2.18Glycoalbumin (%)20.3 ± 3.0Intact proinsulin (pmol/L)19.3 ± 5.8Urinary C-peptide immunoreactivity (μg/day)82.5 ± 36.4HOMA-β24.3 ± 16.6HOMA-IR1.86 ± 1.04Previous antidiabetic medications Sulfonylureas11 Biguanides (metformin)6 Thiazolidinedione3 α-Glucosidase inhibitor1 Glinide1 None1*HOMA-β* homeostasis model assessment for β cell function, *HOMA-IR* homeostasis model assessment for insulin resistance, *SD* standard deviation

Postprandial Changes in Laboratory Values {#Sec9}
-----------------------------------------

Table [2](#Tab2){ref-type="table"} shows concentrations of PG, IRI, glucagon, active GLP-1, and total GIP before (i.e., on the first day of the calorie-restricted diet) and after sitagliptin treatment, as well as their AUCs.Table 2Changes in plasma concentrations of glucose, immunoreactive insulin (IRI), glucagon, and incretins throughout meal tolerance tests, and area under the concentration--time curves, before and after sitagliptin treatmentLaboratory valueTimingTime after meal (min)AUC~0--2h~AUC~0--4h~0153060120240Glucose \[mg/dL (mmol/L)\]Before154 ± 39 (8.5 ± 2.2)166 ± 42 (9.2 ± 2.3)203 ± 45 (11.3 ± 2.5)\*\*\*255 ± 66 (14.2 ± 3.7)\*\*\*259 ± 82 (14.4 ± 4.6)\*\*\*180 ± 69 (10.0 ± 3.8)\*\*457 ± 115 (25.4 ± 6.4)896 ± 248 (49.7 ± 13.8)After133 ± 34 (7.4 ± 1.9)^\#^153 ± 37 (8.5 ± 2.1)\*148 ± 40 (8.2 ± 2.2)^\#\#^201 ± 55 (11.2 ± 3.1)\*\*\*^,\#\#^168 ± 59 (9.3 ± 3.3)\*\*\*^,\#\#^123 ± 43 (6.8 ± 2.4)^\#\#^369 ± 108 (20.5 ± 6.0)^†††^701 ± 246 (38.9 ± 13.7)^†††^IRI (μU/mL)Before5.04 ± 2.4011.37 ± 7.57\*14.22 ± 9.05\*\*\*19.10 ± 7.29\*\*\*26.79 ± 19.08\*\*\*10.52 ± 6.57\*34.0 ± 14.968.3 ± 35.5After6.07 ± 3.428.80 ± 4.6715.56 ± 6.64\*\*\*20.70 ± 8.99\*\*\*32.28 ± 18.42\*\*\*10.44 ± 7.33\*36.3 ± 16.775.0 ± 37.1Glucagon (pg/mL)Before80.6 ± 32.494.9 ± 31.1\*\*\*104.1 ± 33.1\*\*\*98.8 ± 31.6\*\*\*94.5 ± 27.7\*\*\*86.5 ± 26.1\*195 ± 57376 ± 105After81.3 ± 33.188.7 ± 33.1\*92.5 ± 32.4\*\*\*91.3 ± 32.7\*\*\*84.4 ± 29.181.0 ± 23.9180 ± 57^†^349 ± 105^††^Active GLP-1 (pmol/L)Before3.13 ± 1.024.28 ± 2.937.16 ± 4.147.35 ± 5.167.84 ± 7.42--10.5 (8.5, 15.2)--After5.28 ± 3.559.69 ± 6.79\*\*^,\#\#^14.58 ± 7.01\*\*\*^,\#\#^12.95 ± 8.79\*\*\*^,\#\#^19.03 ± 12.85\*\*\*^,\#\#^--26.4 (16.7, 32.4)^‡^--Total GIP (pmol/L)Before11.2 ± 6.341.5 ± 26.8\*\*117.0 ± 67.2\*\*\*122.3 ± 87.4\*\*\*76.5 ± 40.7\*\*\*--186 ± 106--After7.2 ± 4.440.2 ± 23.3\*\*109.9 ± 52.7\*\*\*97.3 ± 54.5\*\*\*57.0 ± 27.6\*\*\*--154 ± 73--Data expressed as mean ± standard deviation or median with quartile values (25 %, 75 %)*AUC* ~*0---2h*~ area under the concentration--time curve from time zero to 2 h, *AUC* ~*0--4h*~ area under the concentration--time curve from time zero to 4 h, *GLP-1* glucagon-like peptide-1, *GIP* glucose-dependent insulinotropic polypeptide, *IRI* immunoreactive insulin\**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 vs. 0 min, ^\#^ *p* \< 0.05 and ^\#\#^ *p* \< 0.001 vs. before sitagliptin treatment (determined by ad hoc Fisher's least significant differences procedure after two-way repeated measures ANOVA). ^†^ *p* \< 0.05, and ^††^ *p* \< 0.01, and ^†††^ *p* \< 0.001, and ^‡^ *p* = 0.003 vs. before sitagliptin treatment (determined by paired *t* test and Wilcoxon signed rank test, respectively)

Figure [1](#Fig1){ref-type="fig"} summarizes the results for glucose. With sitagliptin treatment, glucose was significantly lower at all timepoints, except 15 min, throughout the MTT, including 0 min, compared with equivalent values for the day before sitagliptin treatment started (i.e., on the first day of the calorie-restricted diet). With sitagliptin, AUC~0--2h~ and AUC~0--4h~ for glucose were also decreased (both *p* \< 0.001).Fig. 1Meal tolerance test results for glucose: changes in (**a**) plasma concentration and (**b**) area under the concentration--time curve (AUC). \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 versus 0 min, and ^\#^ *p* \< 0.05 and ^\#\#^ *p* \< 0.001 versus before sitagliptin treatment (i.e., calorie-restricted diet only) (determined by Fisher's least significant difference procedure after two-way repeated ANOVA). Differences in AUCs were analyzed by paired *t* test. Graphs were plotted using means ± standard deviation

Figure [2](#Fig2){ref-type="fig"} summarizes the results for glucagon. Before sitagliptin treatment (i.e., on the calorie-restricted diet alone), glucagon at all timepoints throughout the MTT was increased significantly from baseline (0 min). However, after sitagliptin treatment, glucagon was not significantly increased at 120 and 240 min. With sitagliptin, AUC~0--2h~ and AUC~0--4h~ for glucagon were decreased (*p* = 0.016 and *p* = 0.006, respectively).Fig. 2Meal tolerance test results for glucagon: changes in (**a**) plasma concentration and (**b**) area under the concentration--time curve (AUC). \**p* \< 0.05 and \*\*\**p* \< 0.001 versus 0 min (determined by Fisher's least significant difference procedure after two-way repeated ANOVA). Differences in AUCs were analyzed by paired *t* test. Graphs were plotted using means ± standard deviation

Figure [3](#Fig3){ref-type="fig"} summarizes the results for active GLP-1. With sitaglipin, active GLP-1 was significantly higher at all timepoints after 0 min throughout the MTT compared with baseline (0 min) and compared with equivalent values for the day before sitagliptin treatment started. In contrast, before treatment (i.e., on the calorie-restricted diet alone), active GLP showed no significant change from baseline (0 min) at any timepoint. Sitagliptin increased AUC~0--2h~ for active GLP-1 (*p* \< 0.001).Fig. 3Meal tolerance test results for active glucagon-like peptide-1: changes in (**a**) plasma concentration and (**b**) area under the concentration--time curve (AUC). \*\**p* \< 0.01 and \*\*\**p* \< 0.001 versus 0 min, and ^\#\#^ *p* \< 0.001 versus before sitagliptin (determined by Fisher's least significant difference procedure method after two-way repeated ANOVA). Differences in AUCs were analyzed by Wilcoxon signed rank test. Panel **a** was plotted using means ± standard deviation, and panel **b** using medians and quartile values (minimum 25 %, and maximum 75 %)

Figure [4](#Fig4){ref-type="fig"} summarizes the results for total GIP. Both before and after sitagliptin treatment, total GIP at all timepoints throughout the MTT was increased significantly from baseline (0 min).Fig. 4Meal tolerance test results for total glucose-dependent insulinotropic peptide: changes in (**a**) plasma concentration and (**b**) area under the concentration--time curve (AUC). \*\**p* \< 0.01 and \*\*\**p* \< 0.001 versus 0 min (determined by Fisher's least significant difference procedure after two-way repeated ANOVA). Graphs were plotted using means ± standard deviation

Adverse Reactions {#Sec10}
-----------------

Major adverse reactions were mild gastric symptoms, such as nausea and upper abdominal discomfort. No severe adverse reactions were observed.

Discussion {#Sec11}
==========

In the present study, we investigated the very short-term effects of sitagliptin 50 mg on insulin and glucagon by using MTTs to measure relevant laboratory values in 15 Japanese patients with type 2 diabetes, and to clarify the mechanism by which sitagliptin lowers blood glucose. In the very short-term (after 3 days of sitagliptin treatment), the postprandial glucose concentration was significantly lower than the concentration on the day before sitagliptin treatment started, when the patients had started a calorie-restricted diet. With sitagliptin, postprandial PG was significantly decreased at all but one timepoint throughout the MTT, the AUC~0--2h~ and AUC~0--4h~ were not significantly increased for IRI but were significantly decreased for glucagon, active GLP-1 was significantly increased at all timepoints after 0 min throughout the MTT, and the AUC~0--2h~ for active GLP-1 was significantly increased. These results are discussed and interpreted in turn below. After 3 days of sitagliptin treatment, postprandial PG was significantly decreased at all but one timepoint throughout the MTT, compared with equivalent values for the calorie-restricted diet alone. This finding is consistent with those of previous studies, in that the rapid effects of sitagliptin plateau after 2 days \[[@CR11]\]. The effects of sitagliptin on glucose are caused by its enhancement of insulin secretion and suppression of glucagon secretion \[[@CR12]\]. The effects of sitagliptin on blood glucose have been attributed to glucose-dependent endogenous insulin secretion and glucagon suppression in the middle- or long-term. In our study, we investigated these effects in the very short-term, so our findings are novel in this respect. Patients received the same calorie-restricted diet (25 kcal/kg daily) and underwent MTT to determine the effects of sitagliptin. Therefore the calorie-restricted diet may have contributed to the observed changes in postprandial PG by causing glucose toxicity, so the improvement may not be attributable to sitagliptin alone.

We found that the AUC~0--2h~ and AUC~0--4h~ for IRI did not increase significantly. In contrast, with sitagliptin, the AUC~0--2h~ and AUC~0--4h~ for glucagon were significantly decreased. Therefore, the improvement in postprandial blood glucose shown in the present study may be more strongly associated with suppression of glucagon secretion than with enhancement of insulin secretion with sitagliptin treatment in the very short-term. This finding contrasts with the results of previous studies, which have shown that DPP-4 inhibitors, including sitagliptin, may improve acute insulin response in Japanese patients with type 2 diabetes by increasing early-phase insulin secretion \[[@CR6], [@CR13]\]. The previous studies had a longer follow-up period (about 12 weeks), and therefore secondary effects, including glucose toxicity, could have contributed to the response. In contrast, our study was very short-term, so our results reflect the direct effects of sitagliptin.

An increase in intraislet insulin would suppress glucagon secretion from α cells in a paracrine manner. The intraislet interaction of α and β cells may suppress glucagon secretion in the absence of changes to insulin concentration in the peripheral circulation \[[@CR14]\]. Glucagon secretion may be suppressed either by a secondary effect, in response to increased intraislet insulin concentration, or by direct inhibition, through the potentiation of active GLP-1 in plasma.

In the present study, with sitagliptin, active GLP-1 was significantly increased at all timepoints after 0 min throughout the MTT compared with equivalent values for the calorie-restricted diet alone, and the AUC~0--2h~ for active GLP-1 increased significantly. In contrast, the AUC~0--2h~ for IRI was barely increased. We believe that the observed suppression of glucagon secretion may result at least partly from a direct effect on active GLP-1 rather than a response to increased insulin secretion from β cells. It has been suggested that suppression of glucagon secretion by GLP-1 involves a direct action on pancreatic α cells as well as an indirect action through somatostatin-secreting δ cells \[[@CR15]\]. However, this proposed mechanism remains controversial, with contradictory reports arguing against the expression of GLP-1 receptors on α cells \[[@CR16]\].

GIP is secreted from K cells in the upper portion of the small intestine in response to stimulation by ingestion of glucose and fats. GIP, like GLP-1, could be inactivated by DPP-4. Sitagliptin increases plasma concentrations of active GIP by inhibiting DPP-4. Conversely, sitagliptin decreases plasma concentrations of total GLP-1 and total GIP \[[@CR17]\]. In the present study, the AUC~0--2h~ for total GIP decreased only slightly with sitagliptin treatment. This effect is caused partly by negative feedback from its active form \[[@CR18]\]. We previously reported that plasma GLP-1 is more associated with inhibition of glucagon secretion, and that plasma GIP is more associated with promotion of insulin secretion, in healthy subjects \[[@CR19]\]. However, in patients with type 2 diabetes, the effect of GIP on insulin secretion may be reduced; consequently, the promotion of insulin secretion is primarily mediated by GLP-1.

Impaired insulin secretion is a major pathophysiological feature of type 2 diabetes. Decreased or delayed insulin secretion is responsible for increases in postprandial PG, especially in the early stages of the disease. Excessive and/or paradoxical secretion of glucagon, even in the hyperglycemic condition, also contributes to increased postprandial hyperglycemia. We found in a previous morphological study that as well as a decrease in the number of β cells, there is an increase in the number of α cells in pancreatic islets in patients with long-standing type 2 diabetes \[[@CR20]\].

Our findings suggest that an increase in GLP-1 and suppression of glucagon secretion may underlie any early improvement in PG caused by sitagliptin. However, a larger-scale comparative study is necessary to confirm this mechanism of action and to identify any patient groups in whom these effects are more easily recognized. The finding that patients receiving sitagliptin had a rapid improvement in PG may be useful when deciding the timing and optimal treatment regimen for patients with type 2 diabetes.

The results of the present study also suggest that glucagon suppression may cause hypoglycemia in the early stages of coadministration of sitagliptin and insulin or other insulin secretagogues. Therefore, careful attention must be paid to monitoring patients with low insulin secretory capacity.

In conclusion, sitagliptin may contribute to the rapid improvement of postprandial PG in Japanese patients with type 2 diabetes who are on a calorie-restricted diet. We suggest that any early reduction in blood glucose attributable to sitagliptin results mainly from suppression of excessive glucagon secretion. Major adverse reactions were limited to mild gastric symptoms.

Study Limitations and Future Research {#Sec12}
=====================================

This was a single-arm study without a control group on a calorie-restricted diet but without sitagliptin treatment. It was not possible to determine the relative contributions of diet and sitagliptin to the improvement in PG, increase in active GLP-1, and suppression of glucagon secretion. Therefore, it may not be appropriate to generalize the findings of the present study to Japanese patients with type 2 diabetes. Our next study will involve a greater number of patients and include a control group. Thus, we aim to confirm the results of the present study and to provide findings that are valid for the general population of Japanese patients with type 2 diabetes.
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